EcoDrugPlus

Glycogen Synthase Kinase 3 Alpha B

Ensembl ID : ENSSMAG00000008999
Gene Symbol: GSK3AB
1 Cross references
186 Possible Orthologues:

Glycogen Synthase Kinase 3 Beta, Genome Duplicate A

Ensembl ID : ENSSMAG00000018406
Gene Symbol: GSK3BA
3 Cross references
222 Possible Orthologues:

Gonadotropin-Releasing Hormone Ii Receptor-Like

Ensembl ID : ENSSMAG00000020837
Gene Symbol: LOC118311562
2 Cross references
135 Possible Orthologues:

Group 10 Secretory Phospholipase A2

Ensembl ID : ENSSMAG00000005441
Gene Symbol: ZGC:92162
3 Cross references
232 Possible Orthologues:

Growth Hormone Secretagogue Receptor A

Ensembl ID : ENSSMAG00000015861
Gene Symbol: GHSRA
3 Cross references
212 Possible Orthologues:

Guanylate Cyclase 1 Soluble Subunit Alpha 1

Ensembl ID : ENSSMAG00000008120
Gene Symbol: GUCY1A1
1 Cross references
201 Possible Orthologues:

Guanylate Cyclase 1 Soluble Subunit Beta 1

Ensembl ID : ENSSMAG00000008170
Gene Symbol: GUCY1B1
1 Cross references
210 Possible Orthologues:

Heat Shock Protein 90, Alpha (Cytosolic), Class A Member 1, Tandem Duplicate 1

Ensembl ID : ENSSMAG00000006949
Gene Symbol: HSP90AA1.1
1 Cross references
330 Possible Orthologues:

Heat Shock Protein 90, Alpha (Cytosolic), Class A Member 1, Tandem Duplicate 2

Ensembl ID : ENSSMAG00000006974
Gene Symbol: HSP90AA1.2
1 Cross references
345 Possible Orthologues:

Heat Shock Protein 90, Alpha (Cytosolic), Class B Member 1

Ensembl ID : ENSSMAG00000002596
Gene Symbol: HSP90AB1
3 Cross references
339 Possible Orthologues:

High Mobility Group Box 1a

Ensembl ID : ENSSMAG00000004055
Gene Symbol: HMGB1A
3 Cross references
511 Possible Orthologues:

High Mobility Group Box 1b

Ensembl ID : ENSSMAG00000006047
Gene Symbol: HMGB1B
3 Cross references
509 Possible Orthologues:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).